61874-04-2

Usage

Uses

Used in Fragrance and Flavor Industry:
4-HYDROXY-3-CARBOXALDEHYDEACETIC ACID METHYL ESTER is used as a flavoring agent in food and beverages for its sweet, fruity aroma, enhancing the taste and aroma profile of various products.
Used in Pharmaceutical Synthesis:
4-HYDROXY-3-CARBOXALDEHYDEACETIC ACID METHYL ESTER is used as an intermediate in the synthesis of pharmaceuticals due to its unique chemical structure and properties, contributing to the development of new drugs with potential therapeutic benefits.
Used in Agricultural Products:
4-HYDROXY-3-CARBOXALDEHYDEACETIC ACID METHYL ESTER is used in the development of agricultural products, such as pesticides and fertilizers, leveraging its chemical properties to improve crop yield and protect plants from diseases.
Used in Medicinal Applications:
4-HYDROXY-3-CARBOXALDEHYDEACETIC ACID METHYL ESTER is used as a potential candidate for medicinal applications due to its antioxidant and anti-inflammatory properties, which may contribute to the treatment of various diseases and conditions.

InChI:InChI=1/C10H10O4/c1-14-10(13)5-7-2-3-9(12)8(4-7)6-11/h2-4,6,12H,5H2,1H3

Upstream product

• 871266-57-8 sodium salt of [4-hydroxy-3-(hydroxysulfomethyl)phenyl]acetic acid methyl ester 
• 1576243-71-4 sodium salt of [4-hydroxy-3-(hydroxysulfomethyl)phenyl]acetic acid methyl ester 
• 156-38-7 4-hydroxyphenylacetate 
• 50-00-0 formaldehyd 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 

Downstream Products

• 277313-22-1 methyl (3-bromo-5-formyl-4-hydroxyphenyl)acetate 
• 609804-32-2 methyl 2-(3-cyano-4-hydroxyphenyl)acetate 
• 871266-57-8 sodium salt of [4-hydroxy-3-(hydroxysulfomethyl)phenyl]acetic acid methyl ester 
• 875050-49-0 methyl [3-formyl-4-(2-iodobenzyloxy)phenyl]acetate 
• 1421949-02-1 methyl 2-(3-(2,2-dibromovinyl)-4-hydroxyphenyl)acetate 
• 1422166-88-8 C₂₈H₂₃ClN₂O₃ 
• 1421948-85-7 C₃₁H₂₈N₂O₅ 
• 1422167-02-9 C₃₁H₂₇ClN₂O₂ 
• 1422167-03-0 C₃₂H₃₀N₂O₂ 
• 1422166-89-9 C₂₉H₃₄N₂O₃ 
• 1422166-90-2 C₃₀H₂₆N₂O₂ 
• 1422166-92-4 C₂₉H₂₆N₂O₃ 
• 1422053-25-5 (S)-N-((2,4-dimethylphenyl)(phenyl)methyl)-2-(2-isonicotinoylbenzofuran-5-yl)acetamide 
• 1421949-53-2 2-(2-(hydroxy(3,5-dimethylisoxazol-4-yl)methyl)benzofuran-5-yl)-N-((2,4-dimethylphenyl)(phenyl)methyl)acetamide 

Relevant academic research and scientific papers

MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF

The use of novel 2-hydroxybenzylamine derivatives as scavengers of isolevuglandins.

Phosphine-catalyzed sequential (2+3)/(2+4) annulation of γ-vinyl allenoates: Access to the synthesis of chromeno[4,3-: B] pyrroles

A phosphine-catalyzed cascade (2+3)/(2+4) cyclization reaction of γ-vinyl allenoates with aldimine esters has been developed to provide a series of chromeno[4,3-b]pyrrole derivatives that contain three contiguous stereogenic centers. The method gives a good yield, excellent chemoselectivity and diastereoselectivity under mild conditions.

NEW COMPOUNDS AND USES THEREOF FOR DETECTION OF TARGET MOLECULES IN A SAMPLE

The present invention relates to new profluorophores and conjugates thereof and their use for the detection of target molecule in a sample, in particular nucleic acid target molecules. The invention relates to new profluorophores and new fluorophores and methods of use thereof particularly useful in the fields of diagnostics and quality control.

Identification of a New Class of Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors Followed by a Structure-Activity Relationship Study

Screening of a small compound library at the three excitatory amino acid transporter subtypes 1-3 (EAAT1-3) resulted in the identification of compound (Z)-4-chloro-3-(5-((3-(2-ethoxy-2-oxoethyl)-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic aci

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE

The invention concerns a liquid pharmaceutical composition comprising: A Factor VIIa polypeptide; A buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and An active site stabilizing agent, which is a compound exhibiting a

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

COMPOUNDS AND METHODS

The present invention relates to no vel retinoid-related orphan receptor gamma (RQRy) modulators and their use in the treatment of diseases mediated by RORy.

The development of benzimidazoles as selective rho kinase inhibitors

Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA).

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders